Keywords
postoperative delirium - cholinesterase activity - cardiac surgery
Introduction
In one of the earliest works on delirium by Engel and Romano,[1] delirium was defined as an analogue to organ failure. This definition has evolved
to the currently widely accepted Diagnostic and Statistical Manual of Mental Disorders,
Fifth Edition (DSM-5) criteria defining delirium as a transient and serious disturbance
in attention and cognition developing over a short period of time, whose symptoms
tend to fluctuate during the day and cannot be explained by a preexisting neurocognitive
disorder.[2]
Postoperative delirium (PD) has been reported to occur in between 3 and 80% of patients
after cardiac surgery.[2]
[3]
[4] It has been shown to be associated with prolonged hospital and intensive care unit
(ICU) stay as well as poor outcomes.[4] PD after cardiac surgery is multifactorial, and its pathophysiology remains incompletely
deciphered. There is ample evidence for a pronounced inflammatory response after cardiac
surgery procedures, especially those on cardiopulmonary bypass. Therefore, it may
be hypothesized that this inflammatory reaction may play a significant role in the
etiology of PD. In this context, an imbalance in the “cholinergic anti-inflammatory
pathway” has been shown to be one underlying mechanism.[5] Plasma cholinesterase (CHE) plays an important role in this pathway as it represents
a converging point of immune and drug-metabolizing systems. This prospective observational
study investigates the association between CHE activity in blood and the development
of PD after cardiac surgery, thereby seeking to assess the diagnostic value of CHE
activity for the development of PD in patients undergoing cardiac surgery.
Methods
All patients consented to participate in this prospective observational study. Postoperative
treatment and data acquisition were performed as part of routine patient care. All
procedures described in this study were in accordance with the Institutional Research
Committee (application number: 26/4/19), National Data Safety Regulations, and the
1964 Helsinki declaration and its last amendment by the 64th WMA General Assembly,
Fortaleza, Brazil, October 2013. Data acquisition was based on our institutional database
and was then de-identified. The EuroSCORE (European System for Cardiac Operative Risk
Evaluation) II was calculated to estimate perioperative mortality.[6]
Inclusion and exclusion criteria have been outlined in [Fig. 1]. The preoperative anticholinergic burden was calculated using the Anticholinergic
Cognitive Burden (ACB) Scale.[7]
[8]
[9] A Mini-Mental State Exam (MMSE) was performed at admission and at discharge.[10] On the ICU, PD was evaluated using the Confusion Assessment Method for the ICU (CAM-ICU)
as well as the Intensive Care Delirium Screening Checklist (ICDSC)[11]
[12] on postoperative day (POD) 1 to 5. All examinations were performed by a single investigator
to rule out bias. CHE (assay of butyrylcholinesterase, BChE) activity was determined
preoperatively, immediately after surgery, on POD 1 to 5, and at discharge.
Fig. 1 Study design.
Induction of anesthesia was performed according to a standardized protocol with remifentanil,
propofol, and rocuronium in adjusted doses. On cardiopulmonary bypass, sevoflurane
and remifentanil were used. In the ICU, sedation was continued with propofol and a
standardized nurse-controlled analgesia protocol with oxycodone was implemented. Furthermore,
in the ICU, a standardized antidelirium protocol was followed, which included early
physiotherapy and mobilization, as well as natural daylight, to reestablish circadian
rhythm.
Cerebrovascular adverse events were defined as new onset of postoperative neurologic
symptoms and associated with a new cerebral lesion confirmed by computed tomography
(CT).[13] Reexplorative surgery was performed in case of pericardial tamponade or surgical
bleeding. Cardiogenic shock was defined as a persistent mean arterial pressure of
less than 65 mm Hg despite inotropic support.[14] Nosocomial pneumonia (NP) was diagnosed according to clinical presentation, elevated
leukocyte and C-reactive protein levels, and/or radiological evidence of pulmonary
infiltrates.
Data were analyzed using the IBM SPSS Statistics Data Editor, version 20 (IBM Corp.,
Armonk, NY). They were tested for normal distribution using the Shapiro–Wilk test
as well as the Kolmogorov–Smirnov test with Lilliefors correction. Categorical variables
were evaluated using the Fisher exact test and continuous variables were evaluated
using the Mann–Whitney U test. The null hypothesis was rejected, and a significant difference was assumed
when p-values were ≤0.05. Multivariate analysis incorporated binary logistic regression
using a forward stepwise (conditional) model, where significance for entry was set
at p < 0.05, and significance for exit was p < 0.10. Results are presented as medians with interquartile ranges and percentages,
respectively.
Results
A total of 270 patients were screened, among whom 107 have been included in this study.
PD was diagnosed in 34 (31.8%) patients, who have been compared with those without
PD.
Baseline Parameters
Patient characteristics are outlined in [Table 1]. Median age was significantly higher in the PD group (71 [62–77] versus 65 [58–71];
p = 0.008). All other baseline parameters were comparable. Regarding the whole cohort,
a total of 19.6% of patients were female. Median EuroSCORE II was 1.6%. Median left
ventricular ejection fraction was 55.0%. A total of 9 (8.4%) patients suffered from
chronic obstructive pulmonary disease (COPD) and 14 (13.1%) from insulin-dependent
diabetes mellitus. Concerning surgical procedures, 50 (46.7%) patients underwent isolated
coronary artery bypass grafting, 28 (26.2%) underwent isolated valve surgery, and
29 (27.1%) underwent combined procedures.
Table 1
Baseline characteristics and surgical details
|
No delirium (n = 73)
|
Delirium (n = 34)
|
p-Value
|
Baseline characteristics
|
Age (years)
|
65 (58–71)
|
71 (62–77)
|
0.008
|
Female (%)
|
12 (16.4)
|
9 (26.5)
|
0.296
|
BMI (kg/m2)
|
27.2 (24.9–31.6)
|
27.0 (23.7–28.9)
|
0.312
|
EuroSCORE II (%)
|
1.6 (1.2–2.7)
|
1.8 (1.2–3.1)
|
0.560
|
LVEF (%)
|
55 (55–55)
|
55 (55–55)
|
0.541
|
Comorbidities
|
Arterial hypertension (%)
|
51 (69.8)
|
21 (61.7)
|
0.406
|
Atrial fibrillation (%)
|
10 (13.7)
|
8 (23.5)
|
0.267
|
Insulin-dependent diabetes (%)
|
11 (15.1)
|
3 (8.8)
|
0.372
|
Chronic kidney disease (%)
|
5 (6.8)
|
4 (11.8)
|
0.461
|
Hyperlipidemia (%)
|
28 (38.4)
|
8 (23.5)
|
0.187
|
Hyperuricemia (%)
|
7 (9.6)
|
2 (5.9)
|
0.716
|
COPD (%)
|
6 (8.2)
|
3 (8.8)
|
1.000
|
Pulmonary hypertension (%)
|
3 (4.1)
|
1 (2.9)
|
1.000
|
Peripheral artery disease (%)
|
2 (2.7)
|
1 (2.9)
|
1.000
|
Coronary artery disease (%)
|
49 (67.1)
|
28 (82.4)
|
0.065
|
Surgical details
|
Isolated CABG (%)
|
36 (49.3)
|
14 (41.2)
|
0.434
|
Single valve surgery (%)
|
18 (24.7)
|
10 (29.4)
|
0.604
|
Combined procedures (%)
|
19 (26.0)
|
10 (29.4)
|
0.715
|
Total duration of surgery (minute)
|
248 (215–291)
|
267 (220–307)
|
0.265
|
Duration of cardiopulmonary bypass (minute)
|
127 (91–158)
|
132 (106–176)
|
0.087
|
Duration of cross-clamping (minute)
|
78 (59–107)
|
91 (65–106)
|
0.301
|
Abbreviations: BMI, body mass index; CABG, coronary artery bypass grafting; COPD,
chronic obstructive pulmonary disease; EuroSCORE, European System for Cardiac Operative
Risk Evaluation; LVEF, left ventricular ejection fraction.
Note: data are presented as medians (25th–75th percentiles) or as absolute numbers
(percentages).
Postoperative Delirium
A total of 34 (31.8%) patients were diagnosed with delirium postoperatively. Among
them, 17 (50.0%) patients were diagnosed with hypoactive delirium, 1 (2.9%) suffered
from hyperactive delirium, and 16 (47.1%) were diagnosed with mixed forms of delirium.
The onset of PD was POD 1 in 15 (44.1%) patients, POD 2 in 10 (29.4%), POD 3 in 6
(17.6%), POD 4 in 1 (2.9%) and POD 5 in 2 (5.9%).
Regarding the MMSE, scores at admission as well as at discharge were significantly
lower in the PD group (p < 0.001 and p = 0.015, respectively). The ACB scale was comparable in both groups. CHE activity
at admission and immediately after surgery did not differ; however, significant differences
were observed in CHE activity on POD 1 to 4 (p = 0.041, p = 0.029, p = 0.015, p = 0.035, respectively), as well as at discharge (p = 0.028) ([Table 2] and [Fig. 2]). Accordingly, independent risk factors for the development of PD identified by
multivariate regression analysis were a low preoperative MMSE score (odds ratio [OR]:
0.732 [95% confidence interval, CI: 0.99–1.11]; p = 0.017), a drop in postoperative CHE activity (preoperative CHE compared with CHE
on POD 0) of more than 50% (OR: 2.609; [95% CI: 1.01–6.44]; p = 0.038), and an early postoperative CHE activity (POD 0) below 4,800 U/L (OR: 9.20
[95% CI: 1.8–47.1]; p = 0.008).
Table 2
MMSE and cholinesterase activity
|
No delirium (n = 73)
|
Delirium (n = 34)
|
p-Value
|
MMSE score
|
MMSE score at admission
|
28 (27–29)
|
27 (25–28)
|
<0.001
|
MMSE score at discharge
|
29 (27–30)
|
28 (26–29)
|
0.015
|
ACB scale
|
ACB scale
|
0 (0–1)
|
0 (0–1)
|
0.759
|
CHE activity
|
Preoperative CHE (U/L)
|
9,728 (8,362–11,134)
|
9,205 (7,688–10,674)
|
0.194
|
CHE POD 0 (U/L)
|
5,876 (5,000–7,208)
|
5,655 (4,561–6,543)
|
0.092
|
CHE POD 1 (U/L)
|
6,116 (5,350–7,218)
|
5,478 (4,656–6,538)
|
0.041
|
CHE POD 2 (U/L)
|
5,277 (4,464–6,079)
|
4,588 (3,734–5,353)
|
0.029
|
CHE POD 3 (U/L)
|
4,923 (4,106–5,627)
|
4,245 (3,584–4,955)
|
0.015
|
CHE POD 4 (U/L)
|
4,838 (4,068–5,933)
|
4,212 (3,578–5,067)
|
0.035
|
CHE POD 5 (U/L)
|
4,980 (4,009–5,942)
|
5,359 (4,471–6,266)
|
0.064
|
CHE at discharge (U/L)
|
6,127 (5,100–7,163)
|
4,201 (3,533–5,623)
|
0.028
|
Postoperative drop in CHE > 50% (%)
|
2 (2.7)
|
7 (20.6)
|
0.002
|
CHE POD 0 < 4,800 U/L (%)
|
14 (19.2)
|
13 (38.2)
|
0.035
|
Abbreviations: ACB, anticholinergic burden; CHE, cholinesterase; MMSE, Mini-Mental
State Examination; POD, postoperative day.
Data are presented as medians (25th – 75th percentiles) or absolute numbers (percentages).
Fig. 2 Perioperative cholinesterase activity. POD, postoperative day.
Outcome
Data on adverse events and outcome are presented in [Table 3]. The incidence of adverse events was comparable between both groups. The most frequent
complication was NP, which was diagnosed in a total of 17 (15.9%) patients. No cerebrovascular
events were observed. Reexplorative surgery was performed in one (0.9%) patient. A
total of 3 (2.8%) patients were readmitted to the ICU. All patients survived to discharge.
Median time on mechanical ventilation was longer in the delirium group (14 [10–27]
vs. 10 [7–14] hours; p = 0.001). Accordingly, length of ICU stay (4 [3–7] vs. 2 [2–4] days; p < 0.001) as well as total hospital stay (14 [10–27] vs. 12 [10–15] days; p = 0.004) were longer in patients with PD.
Table 3
Postoperative complications and outcome
|
No delirium (n = 73)
|
Delirium (n = 34)
|
p-Value
|
Adverse events
|
Reexplorative surgery (%)
|
1 (1.4)
|
0 (0.0)
|
1.000
|
Pacemaker implantation (%)
|
1 (1.4)
|
0 (0.0)
|
1.000
|
Surgical site infection (%)
|
0 (0.0)
|
1 (2.9)
|
0.318
|
Nosocomial pneumonia (%)
|
9 (12.3)
|
8 (23.5)
|
0.162
|
Tracheostomy (%)
|
0 (0.0)
|
1 (2.9)
|
0.318
|
ICU readmission (%)
|
1 (1.4)
|
2 (5.9)
|
0.236
|
Outcomes
|
In-hospital mortality (%)
|
0 (0.0)
|
0 (0.0)
|
–
|
Length of hospital stay (days)
|
12 (10–15)
|
14 (12–20)
|
0.004
|
Length of ICU stay (days)
|
2 (2–4)
|
4 (3–7)
|
<0.001
|
Length of PMV (hours)
|
10 (7–14)
|
14 (10–27)
|
0.001
|
Abbreviations: ICU, intensive care unit; PMV, postoperative mechanical ventilation.
Note: data are presented as medians (25th– 5th percentiles) or as absolute numbers
(percentages).
Discussion
Based on the results of the CESARO[15] trial, which was the first multicentre observational study on the association between
CHE activity and the development of PD in surgical patients, this study focuses on
patients after cardiac surgery. Due to the high incidence of PD in cardiac surgery
and its negative impact on postoperative outcome, the prevention of PD is of high
clinical relevance.[4] Reliable diagnostic tools such as reproducible functional tests or biomarkers, allowing
for early diagnosis and treatment, are still scarce.
As expected, a significant drop of CHE activity was observed in all patients after
cardiac surgery as a result of the inflammatory reaction discussed [previously ([Fig. 2] and [Table 2]). Among the investigated patients, postoperative CHE activity was significantly
lower in the delirium group. Accordingly, a postoperative drop of CHE activity of
more than 50% as well as an early postoperative CHE activity of less than 4,800 U/L
have been identified as an independent risk factor for PD. As the onset of PD occurred
on POD 1 and 2 in the majority of patients (73.5%, n = 25), CHE activity may serve as a suitable marker for early diagnosis of PD. However,
there were several limitations. Its diagnostic value was limited to POD 1 to 4 as
well as to discharge. It was neither a suitable parameter for preoperative discrimination
of patients at risk nor immediately or late after surgery (POD 5). In sum, routine
estimation of CHE activity, that is, by point-of-care tests, may be recommended for
early diagnosis and further monitoring of PD within the limitations discussed previously.
As patients with preexisting risk factors for delirium have been excluded from this
study ([Fig. 1]), the more pronounced postoperative drop of CHE activity in the delirium group supports
the thesis that CHE is not only a diagnostic parameter but also involved in the pathomechanism
of PD. Based on this knowledge, the use of CHE inhibitors (e.g., physostigmine), which
reduce the degradation of synaptic acetylcholine (ACh), has been investigated for
pharmacological treatment.[16]
[17]
[18]
Patients after cardiac surgery are at a particularly high risk of the development
of PD as the use of cardiopulmonary bypass leads to a pronounced inflammatory response
due to several factors such as the blood–air interface, the surface area of the tubing,
and cell damage due to suction. Another contributor to the inflammatory cascade is
ischemia–reperfusion injury due to additional proinflammatory mediators as a response
to the reintroduction of oxygen to tissues.[19] As a result, a systemic inflammatory response syndrome of varying severity is observed
in a substantial number of patients after cardiac surgery. Further precipitating factors
include prolonged duration of surgery, microemboli, air embolisms, systemic inflammation,
sedative agents, and mechanical ventilation.[20]
Focusing on the association between inflammation and CHE activity, the underlying
pathomechanism has been referred to as the “cholinergic anti-inflammatory pathway.”
It is supposed to play an important role in the neuroinflammatory pathway of delirium.[21] An increased burden of serum anticholinergic activity along with suppressed plasma
activity of acetylcholinesterase and BChE leads to the inactivation of circulating
ACh.[21] Along with the oxidative metabolism of several drugs, ACh plays an important role
in the homeostatic control of the immune response. Furthermore, in this state of systemic
inflammation, alterations in the blood–brain barrier (BBB) have been reported. Additional
factors affecting the BBB include hypoxia, ischemia, and pain.[22] As a result, inflammatory agents may pass the BBB, causing functional and structural
changes and thus inducing cognitive impairment.[22]
In this context, preoperative anticholinergic cognitive burden plays an important
role and has, therefore, been evaluated in this study. The ACB scale provides a ranking
of anticholinergic effects of different drugs, predicting the risk of adverse effects
such as delirium.[23] The mechanism of action of several medications involves several ACh receptor subtypes.
It has been reported that muscarinic receptor antagonism was associated with impaired
capability concerning memory and attention.[9] In the investigated study population, ACB scores of both groups were comparable.
Furthermore, PD needs to be differentiated from postoperative cognitive dysfunction
(POCD). Although several risk factors are common in both clinical entities, POCD refers
to deterioration in cognition, temporally associated with surgery, whereas PD is caused
by the inflammatory response associated with the stress of surgery.[24] Patients with PD may appear lucid following emergence from anesthesia and are usually
then diagnosed with classical symptoms such as disorientation and hallucinations.
In the investigated study population, MMSE has been performed, with patients in the
delirium group having lower baseline and discharge scores. A low baseline MMSE score
has been identified as an independent risk factor for the development of PD and may,
thus, serve as a predictive diagnostic tool. In accordance with the transient nature
of PD, a gradual postoperative increase in CHE activity was observed.
It has been reported that PD has been associated with poor outcomes in patients after
cardiac surgery.[4] Accordingly, we observed significantly longer times on mechanical ventilation, a
longer stay in ICU, and a longer total inhospital stay in the delirium group. The
incidence of other adverse events was comparable between both groups ([Table 3]).
Delirium is subdivided into three clinical subtypes: hyperactive, hypoactive, and
mixed form.[20] Hypoactive delirium is characterized by reduced alertness, sedation, and reduction
of motor activity, whereas hyperactive delirium is associated with hypervigilance,
psychotic features (e.g., hallucinations and delusions), and agitation. Mixed forms
represent the most common clinical presentation, which is characterized by overlapping
symptoms of hyper- and hypoactive delirium.[22] In the investigated patient cohort, hypoactive and mixed forms were the predominant
entities.
Conclusions
Our results indicate that routine estimation of CHE activity may serve as an additional
diagnostic tool allowing for early diagnosis and treatment of PD in patients after
cardiac surgery. In addition, our data support the neuroinflammatory etiology of PD
in this setting. Further studies are required, with a focus on preoperative identification
of patients at risk as well as on corresponding therapeutic approaches.